Left ventricular assist device: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Bruce M. Tindall
mNo edit summary
mNo edit summary
 
(6 intermediate revisions by 2 users not shown)
Line 1: Line 1:
{{subpages}}
{{subpages}}
Left Ventricular Assist Device or LVAD
A '''left ventricular assist device''' or '''LVAD''' is a [[pump]] which runs in parallel with a [[heart]] to boost the blood flow. The main reason for a patient to have a LVAD implanted is for [[bridge to transplant]] (BTT) or [[destination therapy]] (DT). Currently, the top three companies in this field are:
 
#[[Thoratec]] - Heartmate2 market capital $2B US
A Left Ventricular Assist Device is a pump which runs in parallel with a heart to boost the blood flow. The main reason for a patient to have a LVAD implanted is for Bridge To Transplant (BTT) or Destination Therapy (DT). Currently, the top three companies in this field are:
#[[Ventracor]] - VentrAssist
1. Thoratec - Heartmate2 market capital $2B US
#[[Heartware]][[Category:Suggestion Bot Tag]]
2. Ventracor - VentrAssist
3. Heartware

Latest revision as of 06:00, 11 September 2024

This article is a stub and thus not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.

A left ventricular assist device or LVAD is a pump which runs in parallel with a heart to boost the blood flow. The main reason for a patient to have a LVAD implanted is for bridge to transplant (BTT) or destination therapy (DT). Currently, the top three companies in this field are:

  1. Thoratec - Heartmate2 market capital $2B US
  2. Ventracor - VentrAssist
  3. Heartware